BackSenhwa Biosciences Overview

Senhwa Biosciences Profit Margin

Valuation check: 6492.TWO's profit margin is -28247.43%, below the Healthcare sector average of 10.58%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-34357.08%
↓ 53.02% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-28247.43%
↓ 1.45% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Senhwa Biosciences (6492.TWO) FAQ

As of the most recent data (June 2026), 6492.TWO shows a profit margin of -28247.43%. That compares with -27844.2% in the prior-year period — down 1.4% year over year. That is below the Healthcare sector average of 10.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6492.TWO's profit margin is now -28247.43% (was -27844.2%) — a 1.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Senhwa Biosciences is outperforming or lagging.

The Healthcare sector average profit margin is about 10.58%. Senhwa Biosciences is at -28247.43%, which is lower that average. That is roughly 267077.1% below the sector mean. Use the comparison chart on this page to see how 6492.TWO stacks up against individual peers as well.

That compares with -27844.2% in the prior-year period — down 1.4% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Senhwa Biosciences with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Senhwa Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -28247.43%) with ownership activity and broader fundamentals.